Back to All Combinations
PTEN Loss + PIK3CA
Intermediate PrognosisGenes Involved
PTEN Loss
PIK3CA
Recommended Treatments
Standard chemotherapy
PI3K inhibitors (trials)
Treatments to Avoid
No specific contraindications noted
Key Statistics
4.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Double PI3K pathway activation. May benefit from PI3K pathway inhibitors in trials.
Information
Category: General
Evidence Level: C
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.